It represents the most common acute optic neuropathy in adults over 50 years of age, affecting approximately 2 to 10 per 100,000 individuals annually in this age group in the United States
Consider the numbers: in the SURMOUNT-1 trial [1] , participants on the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks
These details can help a healthcare provider understand how the body is responding to treatment and whether any changes are related to tirzepatide or to something else
Renal Impairment: In patients treated with GLP-1 receptor agonists, including Saxenda , there have been reports of acute renal failure and worsening of chronic renal failure, usually in association with nausea, vomiting, diarrhea, or dehydration, which may sometimes require hemodialysis
The medication is structurally modified to resist degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and includes an albumin-binding side chain, which extends its duration of action compared to native GLP-1